Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | SLC10A2 | Q12908 | 16/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21585926 | 0.89 | SLC10A2 (0.35) | NR1H4SLC10A2 | |
| SCHEMBL30912760 | 0.89 | SLC10A2 (0.35) | NR1H4SLC10A2 | |
| SCHEMBL5222558 | 0.88 | NR1H4 (0.43) | NR1H4SLC10A2 | |
| SCHEMBL23375114 | 0.82 | NR1H4 (0.44) | NR1H4SLC10A2 | |
| SCHEMBL21585979 | 0.82 | SLC10A2 (0.39) | NR1H4SLC10A2 | |
| SCHEMBL23375160 | 0.81 | NR1H4 (0.44) | NR1H4SLC10A2 | |
| SCHEMBL22286375 | 0.81 | SLC10A2 (0.43) | SLC10A2 | |
| SCHEMBL5230346 | 0.81 | SLC6A2 (0.36) | SLC10A2 | |
| SCHEMBL28530366 | 0.81 | NR1H4 (0.37) | NR1H4SLC10A2 | |
| SCHEMBL23375108 | 0.81 | NR1H4 (0.49) | NR1H4SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | NR1H4 7/4885SLC10A2 1/4885SLC6A9 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.